A Phase 3 interventional study of tadalafil and tadalafil in Impotence, sponsored by Eli Lilly and Company. Completed at 1 site in Germany. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-10-22.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.
Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 22nd largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2004, is one of 19 in phase 3, and was the 11th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Surgical Outcomes Research Centre (SOuRCe) · Sites in Australia
Ages 18+ · Men only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Men only
Beni-Suef University · Sites in Egypt
Ages 30–70 · Men only
Mansoura University · Sites in Egypt
Ages 21+ · Men only
Aswan University Hospital · Sites in Egypt
Ages 21+ · Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 21 · Phase 4 26
First in 2002; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 298 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 199 across the 56 interventional studies. Of the 42 that completed or were terminated, 13 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 57 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
28 studies in Erectile Dysfunction by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 28 finished, 14 (50%) have results posted.
Among the 28 studies in Erectile Dysfunction by Eli Lilly and Company, this one is the 19th largest by enrollment, is one of 5 that started in 2004, is one of 13 in phase 3, and was the 7th registered.
Eli Lilly and Company’s Erectile Dysfunction studies by the year they started, since 2002.
3 of the studies testing tadalafil in Erectile Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07642505Beni-Suef UniversityL-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | 2026-11 |
| NCT07391579Mansoura UniversityDaily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients | 2026-12 |
| NCT07753720Al-Azhar UniversityDaily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies testing tadalafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 28 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study to evaluate the safety and effectiveness of 2.5 mg and 5 mg tadalafil when taken by men with diabetes mellitus who have problems getting and maintaining an erection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.5 mg tadalafil
Drug: tadalafil
5 mg tadalafil
Drug: tadalafil
Drug: placebo
2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
Also known as: LY450190, Cialis, IC351
5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
Also known as: LY450190, Cialis, IC351
Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
Effectiveness measured by IIEF score of questions 1-5 and 15 plus the percentages of positive responses to questions 2 and 3 in the SEP diary
Time frame: 12 weeks
Change in the GAQ, SEP, IIEF, SEAR, and RSE scores.
Time frame: 12 weeks
The record gives a start of Oct 2004 and a completion of May 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil